FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387472795> ?p ?o ?g. }

• W4387472795 abstract "During the COVID-19 pandemic, SARS-CoV-2 detection using nucleic acid amplification tests (NAATs) played a key role in clinical management and public health interventions. However, mutations could jeopardize NAAT-based detection if they occur in the NAAT target site, potentially resulting in false negative results. However, mutation monitoring is challenged as the exact location of commercial NAAT target sites is not divulged by manufacturers. This study sequenced commercial SARS-CoV-2 NAAT target sites to assess the impact of mutations occurring in these regions. The resulting sequences for the Xpert, Cobas, and ID NOW SARS-CoV-2 assays were queried against SARS-CoV-2 genome databases to identify mutations in circulating strains. Synthetic DNAs and clinical specimens harboring NAAT target site mutations were used to assess mutation impact. Of 17,600 NAAT target site mutation occurrences in a genome database, 269 compromised target detection. These represented 24 unique mutations that reduced NAAT target sensitivity and nine led to target detection failure. Only seven of these mutations were previously recognized. Overall, this reactive strategy along with passive surveillance identified 29 novel mutations that compromised detection with Xpert and Cobas targets. Knowledge of commercial NAAT target sites, paired with a strategy for mutation impact assessment and ongoing genetic surveillance, provided a robust framework for commercial NAAT target site quality assurance. The question remains of who should be responsible for NAAT target site quality assurance, but collaborative efforts between methods users, industry, and regulatory agencies would be ideal. Molecular tests like polymerase chain reaction were widely used during the COVID-19 pandemic but as the pandemic evolved, so did SARS-CoV-2. This virus acquired mutations, prompting concerns that mutations could compromise molecular test results and be falsely negative. While some manufacturers may have in-house programs for monitoring mutations that could impact their assay performance, it is important to promptly report mutations in circulating viral strains that could adversely impact a diagnostic test result. However, commercial test target sites are proprietary, making independent monitoring difficult. In this study, SARS-CoV-2 test target sites were sequenced to monitor and assess mutations impact, and 29 novel mutations impacting SARS-CoV-2 detection were identified. This framework for molecular test target site quality assurance could be adapted to any molecular test, ensuring accurate diagnostic test results and disease diagnoses." @default.
• W4387472795 created "2023-10-11" @default.
• W4387472795 creator A5004182752 @default.
• W4387472795 creator A5004381991 @default.
• W4387472795 creator A5009893274 @default.
• W4387472795 creator A5039817977 @default.
• W4387472795 creator A5043618777 @default.
• W4387472795 creator A5073812612 @default.
• W4387472795 creator A5077810093 @default.
• W4387472795 creator A5078272220 @default.
• W4387472795 creator A5081585044 @default.
• W4387472795 creator A5093032260 @default.
• W4387472795 date "2023-10-10" @default.
• W4387472795 modified "2023-10-16" @default.
• W4387472795 title "Neglected SARS-CoV-2 variants and potential concerns for molecular diagnostics: a framework for nucleic acid amplification test target site quality assurance" @default.
• W4387472795 cites W1883819657 @default.
• W4387472795 cites W2099153677 @default.
• W4387472795 cites W2127043657 @default.
• W4387472795 cites W2479317113 @default.
• W4387472795 cites W2605343262 @default.
• W4387472795 cites W3025007192 @default.
• W4387472795 cites W3034943191 @default.
• W4387472795 cites W3035294517 @default.
• W4387472795 cites W3042099287 @default.
• W4387472795 cites W3042504804 @default.
• W4387472795 cites W3087441472 @default.
• W4387472795 cites W3090205764 @default.
• W4387472795 cites W3098305151 @default.
• W4387472795 cites W3099331167 @default.
• W4387472795 cites W3124205961 @default.
• W4387472795 cites W3158973451 @default.
• W4387472795 cites W3161320406 @default.
• W4387472795 cites W3161834201 @default.
• W4387472795 cites W3164005727 @default.
• W4387472795 cites W3180802407 @default.
• W4387472795 cites W3183017070 @default.
• W4387472795 cites W3185481978 @default.
• W4387472795 cites W3190056407 @default.
• W4387472795 cites W3201039121 @default.
• W4387472795 cites W3216427703 @default.
• W4387472795 cites W4200215210 @default.
• W4387472795 cites W4206612339 @default.
• W4387472795 cites W4212777014 @default.
• W4387472795 cites W4213196766 @default.
• W4387472795 cites W4224209884 @default.
• W4387472795 cites W4225348791 @default.
• W4387472795 cites W4280639198 @default.
• W4387472795 cites W4283582423 @default.
• W4387472795 cites W4285086369 @default.
• W4387472795 cites W4285595759 @default.
• W4387472795 cites W4306732672 @default.
• W4387472795 cites W4308585205 @default.
• W4387472795 cites W4309008702 @default.
• W4387472795 cites W4309600417 @default.
• W4387472795 doi "https://doi.org/10.1128/spectrum.00761-23" @default.
• W4387472795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37815347" @default.
• W4387472795 hasPublicationYear "2023" @default.
• W4387472795 type Work @default.
• W4387472795 citedByCount "0" @default.
• W4387472795 crossrefType "journal-article" @default.
• W4387472795 hasAuthorship W4387472795A5004182752 @default.
• W4387472795 hasAuthorship W4387472795A5004381991 @default.
• W4387472795 hasAuthorship W4387472795A5009893274 @default.
• W4387472795 hasAuthorship W4387472795A5039817977 @default.
• W4387472795 hasAuthorship W4387472795A5043618777 @default.
• W4387472795 hasAuthorship W4387472795A5073812612 @default.
• W4387472795 hasAuthorship W4387472795A5077810093 @default.
• W4387472795 hasAuthorship W4387472795A5078272220 @default.
• W4387472795 hasAuthorship W4387472795A5081585044 @default.
• W4387472795 hasAuthorship W4387472795A5093032260 @default.
• W4387472795 hasBestOaLocation W43874727951 @default.
• W4387472795 hasConcept C104317684 @default.
• W4387472795 hasConcept C159047783 @default.
• W4387472795 hasConcept C179786068 @default.
• W4387472795 hasConcept C2777391075 @default.
• W4387472795 hasConcept C2909633786 @default.
• W4387472795 hasConcept C501734568 @default.
• W4387472795 hasConcept C54355233 @default.
• W4387472795 hasConcept C70721500 @default.
• W4387472795 hasConcept C71924100 @default.
• W4387472795 hasConcept C86803240 @default.
• W4387472795 hasConceptScore W4387472795C104317684 @default.
• W4387472795 hasConceptScore W4387472795C159047783 @default.
• W4387472795 hasConceptScore W4387472795C179786068 @default.
• W4387472795 hasConceptScore W4387472795C2777391075 @default.
• W4387472795 hasConceptScore W4387472795C2909633786 @default.
• W4387472795 hasConceptScore W4387472795C501734568 @default.
• W4387472795 hasConceptScore W4387472795C54355233 @default.
• W4387472795 hasConceptScore W4387472795C70721500 @default.
• W4387472795 hasConceptScore W4387472795C71924100 @default.
• W4387472795 hasConceptScore W4387472795C86803240 @default.
• W4387472795 hasLocation W43874727951 @default.
• W4387472795 hasLocation W43874727952 @default.
• W4387472795 hasOpenAccess W4387472795 @default.
• W4387472795 hasPrimaryLocation W43874727951 @default.
• W4387472795 hasRelatedWork W1497983014 @default.
• W4387472795 hasRelatedWork W2053247916 @default.
• W4387472795 hasRelatedWork W2099484649 @default.
• W4387472795 hasRelatedWork W2106038390 @default.
• W4387472795 hasRelatedWork W2117555801 @default.

• next